富马酸伏诺拉生片与泮托拉唑钠肠溶片治疗反流性食管炎的疗效及不良反应比较

Comparison of efficacy and adverse reactions of Vonoprazan fumarate tablets and pantoprazole sodium enteric-coated tablets in the treatment of reflux esophagitis

摘要:

目的 探究富马酸伏诺拉生片（以下简称伏诺拉生）与泮托拉唑钠肠溶片（以下简称泮托拉唑）治疗反流性食管炎（RE）的疗效及不良反应。方法 前瞻性选取2020年6月—2022年6月在上海健康医学院附属崇明医院就诊的114例RE患者。采用随机数字表法分成A和B组，每组57例。A组予以富马酸伏诺拉生治疗，B组予以泮托拉唑钠肠溶片治疗。比较两组疗效、症状评分、胃肠激素水平、炎症水平及不良反应。结果 A组疗效优于B组（P <0.05）。A组治疗前后反流性疾病问卷评分、胃食管反流病问卷评分、血管活性肠肽、胆囊收缩素、白细胞介素-8、诱导型一氧化氮合成酶、核因子-κB、促胃泌素、促胃动素、白细胞介素-10的差值均高于B组（P <0.05）。两组不良反应率比较，差异无统计学意义（P >0.05）。A组复发率低于B组（P <0.05）。结论 与较泮托拉唑比较，伏诺拉生治疗RE疗效更好，症状、胃肠激素及炎症因子水平均有较好改善，且复发率低，用药安全。

Abstract:

Objective To explore the efficacy and adverse reactions of Vonoprazan fumarate tablets (abbreviated as Vonoprazan) and pantoprazole sodium enteric-coated tablets (abbreviated as pantoprazole) in the treatment of reflux esophagitis (RE).Methods A total of 114 RE patients admitted to Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences from June 2020 to June 2022 were prospectively included in this study. They were divided into group A and group B, each with 57 cases, using the random number table method. Group A was treated with Vonoprazan, and group B was treated with pantoprazole. The efficacy, symptom scores, levels of gastrointestinal hormones, the level of inflammation and adverse reactions were compared between the two groups.Results The curative effect of the group A was better than that of the group B (P < 0.05). The differences of the Reflux Disease Questionnaire scores, Gastroesophageal Reflux Disease Questionnaire scores, and levels of vasoactive intestinal peptide, cholecystokinin, interleukin-8, inducible nitric oxide synthase, nuclear factor-κB, gastrin, motilin and interleukin-10 before and after the treatment in the group A were higher than those in the group B (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). The recurrence rate of the group A was lower than that of the group B (P < 0.05).Conclusion Compared with pantoprazole, Vonoprazan demonstrates superior therapeutic effects in the clinical treatment of RE, showing better improvement in symptoms and levels of gastrointestinal hormones and inflammatory factors, lower recurrence rate, and fewer safety concerns.